Cannabis Stocks Surge on Trump Rescheduling Comments

Cannabis stocks experienced broad-based gains following former President Trump's remarks indicating he would consider federal marijuana reclassification. The comments represent a notable shift in rhetoric from Trump, who previously maintained a more conservative stance on cannabis policy during his first term.

The market reaction underscores how heavily cannabis valuations depend on federal regulatory developments. Multi-state operators like Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) have traded at compressed multiples compared to traditional consumer goods companies, largely due to federal prohibition constraints that limit banking access and interstate commerce.

Trump's evolving position aligns with broader Republican acceptance of cannabis reform at the state level. With 38 states now operating medical programs and 24 allowing adult-use sales, federal prohibition increasingly conflicts with state-level implementation. This regulatory mismatch creates operational inefficiencies that weigh on cannabis company margins and growth prospects.

The timing proves significant as the Biden administration continues its own rescheduling review through the Department of Health and Human Services. Moving cannabis from Schedule I to Schedule III would eliminate the 280E tax burden that prevents cannabis companies from deducting standard business expenses, potentially improving EBITDA margins by 15-25% across the sector.

Investor enthusiasm reflects the high-stakes nature of federal reform for cannabis valuations. Current market caps remain well below peak levels from 2021, when retail speculation drove cannabis stocks to unsustainable heights. Today's rally suggests institutional investors view bipartisan momentum on rescheduling as increasingly credible, potentially setting the stage for sustained sector outperformance if federal barriers continue eroding.